Table 1.
Characteristics of the study population (Mean ± SEM)
| Vertebral fracture (n=45) | Control (n=45) | p | |
|---|---|---|---|
| Age (years) | 70 ± 1 | 70 ± 1 | 0.99 |
| Race (%) | 0.86 | ||
| Caucasian | 82 | 84 | |
| African American | 9 | 7 | |
| Other | 9 | 9 | |
| Ethnicity (%) | 0.79 | ||
| Hispanic | 20 | 18 | |
| Non-Hispanic | 80 | 82 | |
| BMI (kg/m2) | 28 ± 1 | 27 ± 1 | 0.53 |
| Years since menopause | 22 ± 1 | 20 ± 1 | 0.46 |
| Family history of osteoporosis by BMD (%) | 40 | 33 | 0.78 |
| Family history of fracture (%) | 24 | 22 | 0.92 |
| Tobacco use (%) | 0.24 | ||
| Never | 47 | 33 | |
| Former | 38 | 47 | |
| Current | 7 | 2 | |
| Alcohol use (beverages per day) | 0.5 ± 0.1 | 0.8 ± 0.2 | 0.90 |
| Calcium supplements, total daily dose (mg) | 635 ± 100 | 593 ± 90 | 0.75 |
| Vitamin D supplements, total daily dose (IU) | 1233 ± 279 | 804 ± 228 | 0.06 |
| Hormone replacement therapy (%) | |||
| Past | 38 | 40 | 0.46 |
| Current | 4 | 4 | 0.94 |
| Bisphosphonatesa (%) | |||
| Past | 13 | 4 | 0.13 |
| Current | 13 | 4 | 0.13 |
| Raloxifene (%) | 7 | 4 | 0.76 |
| Thyroxine (%) | 18 | 24 | 0.27 |
a
Prior bisphosphonate use limited to <1 year